Ozmosi | IC-500 Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

IC-500

Alternative Names: ic-500, ic 500, ic500
Clinical Status: Active
Latest Update: 2024-04-27
Latest Update Note: PubMed Publication

Product Description

IC-500 is a HtrA1 (high temperature requirement A serine peptidase 1 protein) Inhibitor being developed by IVERIC Bio. (Sourced from: https://investors.ivericbio.com/news-releases/news-release-details/iveric-bio-reports-second-quarter-2020-operational-highlights)

Mechanisms of Action: HTRA1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: IVERIC bio
Company Location:
Company CEO: Glenn P. Sblendorio
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 0: Geographic Atrophy

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title

04/27/2024

PubMed

 Novel guanidine derivatives targeting leukemia as selective Src/Abl dual inhibitors: Design, synthesis and anti-proliferative activity.

03/01/2023

News Article

 Iveric Bio Reports Fourth Quarter and Full Year 2022 Operational Highlights and Financial Results

11/03/2022

News Article

 Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results

10/06/2022

PubMed

 Response of Soil Bacterial Diversity, Predicted Functions and Co-Occurrence Patterns to Nanoceria and Ionic Cerium Exposure.

07/26/2022

News Article

 Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results

05/04/2022

News Article

 Iveric Bio Reports First Quarter 2022 Operational Highlights and Financial Results

03/02/2022

PubMed

 NBI-921352, a first-in-class, NaV1.6 selective, sodium channel inhibitor that prevents seizures in Scn8a gain-of-function mice, and wild-type mice and rats.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions